Phase I trial of fenretinide (4-HPR, NSC 374551) lym-X-sorb (LXS) oral powder (4-HPR/LXS oral powder) (4-HPR) in adults with solid tumors and lymphomas.
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2012
At a glance
- Drugs Fenretinide (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 07 Mar 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.